CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024
For the nine months, sales was USD 0.130074 million compared to USD 0.310165 million a year ago. Net loss was USD 0.634614 million compared to USD 3.14 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.78 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.78 a year ago.